



CASE D0043 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV306636632US  
Express Mail Label Number

August 18, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 25 2003

TECH CENTER 1600/2900

IN RE APPLICATION OF

CHANG ET AL.

APPLICATION NO: 09/988,971

FILED: NOVEMBER 20, 2001

FOR: CLONING AND EXPRESSION OF HUMAN SLAP-2: A NOVEL  
SH2/SH3 DOMAIN-CONTAINING HUMAN SLAP HOMOLOGUE  
HAVING IMMUNE CELL-SPECIFIC EXPRESSION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

08/20/2003 SZENDIE1 00000056 193880 09988971  
01 FC:1806 180.00 DA

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: August 18, 2003

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



CASE D0043 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV306636632US  
Express Mail Label Number

August 18, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHANG ET AL.

APPLICATION NO: 09/988,971

FILED: NOVEMBER 20, 2001

FOR: CLONING AND EXPRESSION OF HUMAN SLAP-2: A NOVEL  
SH2/SH3 DOMAIN-CONTAINING HUMAN SLAP HOMOLOGUE  
HAVING IMMUNE CELL-SPECIFIC EXPRESSION

RECEIVED

AUG 25 2003

TECH CENTER 1600/2900

MAIL STOP: DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).  
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652


Date: August 18, 2003

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
D0043 NP  
APPLICATION NO.  
09/988,971  
APPLICANT  
CHANG ET AL.  
FILING DATE  
NOVEMBER 20, 2001

Sheet 1 of 1

**RECEIVED**

AUG 25 2003

TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AR	NCBI Accession No. gi:17351918, Loreto, et al., June 3, 2002
AS	NCBI Accession No. gi: 14149916, Loreto, et al., May 7, 2003
AT	Okano, et al. (1991) J. of Neurochemistry 56:560-567

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0043 NP  
APPLICATION NO.  
09/988,971  
APPLICANT  
CHANG ET AL.  
FILING DATE  
NOVEMBER 20, 2001

Group



**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

**RECEIVED**

AUG 25 2003

TECH CENTER 1600/2900

2AA	Stein, et al. (1988) Nucleic Acids Research 16(8):3209-3221
2AB	Zhang, et al (1998) Cell Press 92:83-92
2AC	Chan, et al. (1992) Cell Press 71:649-662
2AD	Chan, et al. (1995) EMBO J. 14(11):2499-2508
2AE	Pawson, et al. (1997) Science 278:2075-2080
2AF	Pandey, et al. (1995) J. of Biological Chemistry 270(33):19201-19204
2AG	Pandey, et al. (2002) J. of Biological Chemistry 277(21):19131-19138
2AH	Wardenburg, et al. (1996) J. of Biological Chemistry 271(33):19641-19644
2AI	Kelly, et al. (2000) Current Opinion in Immunology 12:267-275
2AJ	Myung, et. al. (2000) Current Opinion in Immunology 12:256-266
2AK	Tomlinson, et al. (2000) Review Immunology Today 21(11):584-591
2AL	Tomohiro Kurosaki (1999) Annual Rev. Immunol. 17:555-592
2AM	Holland, et al. (2001) J. Exp. Med. 194(9):1263-1276
2AN	Sosinowski, et al. (2000) J. Exp. Med. 191(3):463-473

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0043 NP  
APPLICATION NO.  
09/988,971  
APPLICANT  
CHANG ET AL.  
FILING DATE  
NOVEMBER 20, 2001


Sheet 3 of 3

**RECEIVED**

AUG 25 2003

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

TECH CENTER 1600/2900



3AA	Loreto, et al. (2002) Molecular and Cellular Biology 22(12):4241-4255
3AB	Williams, et al. (1998) Molecular and Cellular Biology 18(3):1388-1399
3AC	Tang, et al. (1999) Proc. Natl. Acad. Sci. 96:9775-9780
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.